<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Glioma Recurrence Versus Radiation Necrosis?" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/glioma-recurrence-versus-radiation-necrosis/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/glioma-recurrence-versus-radiation-necrosis/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2010-02-28T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Glioma Recurrence Versus Radiation Necrosis?" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-07T07:15:32+00:00","datePublished":"2010-02-28T17:00:00+00:00","description":"Rationale and Objectives","headline":"Glioma Recurrence Versus Radiation Necrosis?","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/glioma-recurrence-versus-radiation-necrosis/"},"url":"https://clinicaltree.github.io/posts/glioma-recurrence-versus-radiation-necrosis/"}</script><title>Glioma Recurrence Versus Radiation Necrosis? | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Glioma Recurrence Versus Radiation Necrosis?</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Glioma Recurrence Versus Radiation Necrosis?</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1267376400" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Feb 28, 2010 </em> </span> <span> Updated <em class="" data-ts="1680851732" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 7, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Yelda Ozsunar MD</a> </em>, <em> <a href="">Mark E. Mullins MD PhD</a> </em>, <em> <a href="">Kenneth Kwong PhD</a> </em>, <em> <a href="">Fred H. Hochberg MD</a> </em>, <em> <a href="">Christine Ament MD</a> </em>, <em> <a href="">Pamela W. Schaefer MD</a> </em>, <em> <a href="">R. Gilberto Gonzalez MD PhD</a> </em>, <em> <a href="">Michael H. Lev MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2581 words"> <em>14 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Distinguishing recurrent glial tumor from radiation necrosis can be challenging. The purpose of this pilot study was to preliminarily compare unenhanced arterial spin-labeled (ASL) imaging, dynamic susceptibility contrast-enhanced cerebral blood volume (DSCE-CBV) magnetic resonance imaging, and positron emission tomographic (PET) imaging in distinguishing predominant glioma recurrence or progression from predominant radiation necrosis in postoperative patients treated with proton-beam therapy.</p><h2 id="methods"><span class="mr-2">Methods</span><a href="#methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Patients with grade II to IV glioma previously treated with surgery and proton-beam therapy were enrolled on the basis of new enhancing nodules or masses with primary differential diagnoses of predominant tumor recurrence or progression versus radiation necrosis. ASL, DSCE-CBV, and PET examinations were assessed by visual qualitative and quantitative analysis for the detection of predominant tumor recurrence. Imaging results were correlated with a clinical-pathologic reference standard.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Thirty patients were studied, resulting in 33 ASL, 32 DSCE-CBV, and 26 PET examinations. On the basis of visual inspection, the sensitivities of PET, ASL, and DSCE-CBV examinations for detecting high-grade tumor foci were 81%, 88%, and 86%, respectively. The highest sensitivity values for quantitative ASL imaging were obtained using a normalized cutoff ratio of 1.3, resulting in sensitivity of 94% for ASL imaging and 71% for DSCE-CBV imaging. When predominant high-grade tumors with superimposed regions of predominant mixed radiation necrosis were excluded, DSCE-CBV sensitivity improved to 90%, but ASL sensitivity remained unchanged.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Compared with DSCE-CBV imaging, ASL imaging may more accurately distinguish predominant recurrent high-grade glioma from radiation necrosis, especially in regions with mixed radiation necrosis, for which DSCE-CBV imaging may underestimate true blood volume because of leakage artifacts.</p><p>Primary central nervous system neoplasia is one of the most frequent causes of death between 15 and 35 years of age . Gliomas constitute &gt;90% of primary brain tumors diagnosed after the second decade of life . Despite treatment with chemotherapy and radiation, including proton-beam therapy (PBT) and other radiosurgery, the majority of these tumors progress and/or recur. Moreover, treatment with radiation remains associated with tissue necrosis that may also lead to clinical deterioration . When a magnetic resonance imaging (MRI) scan of the brain shows a new enhancing lesion after a patient has undergone surgery and radiation for high-grade glioma, the differentiation of predominant recurrent tumor (or progression of tumor) from predominant radiation necrosis is often crucial, because the two entities have different treatment approaches and prognoses .</p><p>Computed tomographic and conventional MRI findings are relatively nonspecific, although some findings on MRI, especially when presenting in combination, may favor a given diagnosis . Positron emission tomographic (PET) and single photon-emission computed tomographic imaging provide additional information regarding tumor metabolism . Although early results with fluorodeoxyglucose (FDG) PET imaging were encouraging, some studies have reported specificities as low as 18%, high cost, and limited availability . Glioma recurrence or progression and radiation necrosis may be frequently mixed (in terms of pathology), and residual microscopic tumor foci are often present, even in so-called pure necrosis cases, further complicating the situation .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-enrollment"><span class="mr-2">Patient Enrollment</span><a href="#patient-enrollment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="brain-tumors"><span class="mr-2">Brain Tumors</span><a href="#brain-tumors" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="clinical-follow-up"><span class="mr-2">Clinical Follow-Up</span><a href="#clinical-follow-up" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="pet-examinations"><span class="mr-2">PET Examinations</span><a href="#pet-examinations" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="mri-examinations"><span class="mr-2">MRI Examinations</span><a href="#mri-examinations" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="asl-imaging"><span class="mr-2">ASL Imaging</span><a href="#asl-imaging" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="dsce-cbv-imaging"><span class="mr-2">DSCE-CBV Imaging</span><a href="#dsce-cbv-imaging" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="data-analysis"><span class="mr-2">Data Analysis</span><a href="#data-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Distribution of Sensitivity and Specificity Values of Predominantly Recurrent or Progressive Versus Nonrecurrent High-grade Tumor</p><p>Modality Total Nonrecurrence Recurrence Sensitivity Specificity ASL imaging 33 12 (36%) 21 (64%) 88% 89% DSCE-CBV imaging 32 10 (33%) 22 (67%) 86% 70% PET imaging 26 12 (46%) 14 (54%) 81% 90% Histopathology 35 12 (34%) 23 (66%)</p><p>ASL, arterial spin-labeled; DSCE-CBV, dynamic susceptibility contrast-enhanced cerebral blood volume; PET, positron emission tomographic.</p><p>The findings are based on grading scores on three-point scale for ASL, DSCE-CBV, and PET imaging in patients treated with proton-beam therapy (Friedman’s test, <em>P</em> &lt; .01 for all three comparisons). Consensus rating scores of 0 and 1 indicated nonrecurrence, whereas a score of 2 indicated high-grade recurrence.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/GliomaRecurrenceVersusRadiationNecrosis/0_1s20S1076633209005960.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/GliomaRecurrenceVersusRadiationNecrosis/0_1s20S1076633209005960.jpg" alt="Figure 1, A 45-year-old man with a history of attempted resection of grade IV glioma, chemotherapy, proton-beam therapy, and subsequent new abnormal enhancing lesion on follow-up magnetic resonance imaging. Positron emission tomographic image ( a ) shows ring-shaped hypermetabolism in the right frontal lobe (arrow). Contrast-enhanced T1-weighted axial image ( b ) illustrates a heterogeneously ring-enhancing lesion at the site of lesion. Both axial arterial spin-labeled ( c ) and dynamic susceptibility contrast-enhanced cerebral blood volume ( d ) maps show ring-shaped hyperperfusion in the contrast-enhancing lesion, suggesting predominant high-grade tumor recurrence, which was confirmed on histopathology." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/GliomaRecurrenceVersusRadiationNecrosis/1_1s20S1076633209005960.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/GliomaRecurrenceVersusRadiationNecrosis/1_1s20S1076633209005960.jpg" alt="Figure 2, A 47-year-old man with a history of attempted resection of grade IV glioma and proton-beam therapy with new abnormal enhancing lesion on follow-up. Positron emission tomographic imaging ( a ) shows hypermetabolism at the site of the lesion on contrast-enhanced T1 axial imaging ( b ). Arterial spin-labeled (ASL) ( c ) and dynamic susceptibility contrast-enhanced cerebral blood volume (DSCE-CBV) ( d ) images show hyperperfusion that correlates with the axial postcontrast T1-weighted image. Note that the lesion is more conspicuous on ASL than on DSCE-CBV imaging. Subsequent surgical resection confirmed predominantly tumor recurrence." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/GliomaRecurrenceVersusRadiationNecrosis/2_1s20S1076633209005960.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/GliomaRecurrenceVersusRadiationNecrosis/2_1s20S1076633209005960.jpg" alt="Figure 3, Receiver-operating characteristic curves for arterial spin-labeled (ASL) and dynamic susceptibility contrast-enhanced cerebral blood volume (DSCE-CBV) images obtained using mean region-of-interest measurement (95% confidence interval for ASL imaging, 0.42–0.97; 95% confidence interval for DSCE-CBV imaging, 0.34–0.97)." class="lazyload" data-proofer-ignore></a></p><p>Table 2</p><p>Test Characteristics for the Detection of Predominant Recurrent or Progressive High-Grade Glioma in PBT-treated Patients, Based on Quantitative ROI Analyses, Applying a Cutoff Ratio of 1.3</p><p>ASL Imaging DSCE-CBV Imaging With Mixed Histology Without Mixed Histology With Mixed Histology Without Mixed Histology Variable ( <em>n</em> = 23) ( <em>n</em> = 18) ( <em>n</em> = 19) ( <em>n</em> = 15) Sensitivity 94% 92% 71% 90% Specificity 50% 50% 40% 40% PPV 88% 85% 77% 75% NPV 12% 15% 15% 16%</p><p>ASL, arterial spin-labeled; DSCE-CBV, dynamic susceptibility contrast-enhanced cerebral blood volume, NPV, negative predictive value; PBT, proton-beam therapy; PPV, positive predictive value; ROI, region of interest.</p><p>The second and fourth columns represent patients excluding mixed high-grade tumor and radiation necrosis.</p><p>Table 3</p><p>Mean Normalized ROI Values Based on Quantitative ROI Analyses of the Perfusion Map Values, Stratified According to Clinical-pathologic Diagnoses</p><p>Normalized ROI ASL Imaging DSCE-CBV Imaging Histopathology ( <em>n</em> = 23) ( <em>n</em> = 19) Predominant radiation necrosis/low-grade tumor 2.0 ± 1.4 ( <em>n</em> = 5) 2 ± 1.5 ( <em>n</em> = 5) Predominant high-grade tumor recurrence 3.9 ± 5 ( <em>n</em> = 13) 2.6 ± 1.8 ( <em>n</em> = 10) Radiation necrosis with mixed high-grade tumor 4.3 ± 1.6 ( <em>n</em> = 5) 1.2 ± 0.3 ( <em>n</em> = 4)</p><p>The differences between the nonrecurrence and predominantly high-grade recurrence for histopathologic subgroups were not statistically significant (Student’s <em>t</em> test).</p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/GliomaRecurrenceVersusRadiationNecrosis/3_1s20S1076633209005960.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/GliomaRecurrenceVersusRadiationNecrosis/3_1s20S1076633209005960.jpg" alt="Figure 4, A 58-year-old man with grade IV glioma and a history of attempted resection, proton-beam therapy, and with a new enhancing lesion on follow-up magnetic resonance imaging. Positron emission tomographic imaging (not shown) shows hypometabolism at the site of the abnormally enhancing left parieto-occipital lesion on contrast-enhanced T1-weighted axial image ( a ). Whereas the arterial spin-labeled (ASL) image ( b ) shows hypoperfusion, the dynamic susceptibility contrast-enhanced cerebral blood volume (DSCE-CBV) image ( c ) shows hyperperfusion of the enhancing lesion that is surrounded with hypoperfused region due to vasogenic edema. Histopathology of this lesion confirmed radiation necrosis. This case therefore demonstrates “true-negative” ASL and “false-positive” DSCE-CBV findings." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusion"><span class="mr-2">Conclusion</span><a href="#conclusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Langleben D.D., Segall G.M.: PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000; 41: pp. 1861-1867.</p><li><p>2. Kleihues P., Soylemezoglu F., Schauble B., et. al.: Histopathology, classification, and grading of gliomas. Glia 1995; 15: pp. 211-221.</p><li><p>3. Bénard F., Romsa J., Hustinx R.: Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 2003; 33: pp. 148-162.</p><li><p>4. Loeffler J.S., Alexander E., Hochberg F.H., et. al.: Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 1990; 19: pp. 1455-1462.</p><li><p>5. Mullins M.E., Barest G.D., Schaefer P.W., et. al.: Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 2005; 26: pp. 1967-1972.</p><li><p>6. Valk P.E., Dillon W.P.: Radiation injury of the brain. AJNR Am J Neuroradiol 1991; 12: pp. 45-62.</p><li><p>7. Ricci P.E., Karis J.P., Heiserman J.E., et. al.: Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol 1998; 19: pp. 407-413.</p><li><p>8. Kahn D., Follett K.A., Bushnell D.L., et. al.: Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994; 163: pp. 1459-1465.</p><li><p>9. Kumar A.J., Leeds N.E., Fuller G.N., et. al.: Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000; 217: pp. 377-384.</p><li><p>10. Roberts H.C., Roberts T.P., Brasch R.C., et. al.: Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: pp. 891-899.</p><li><p>11. Roberts H.C., Roberts T.P., Bollen A.W., et. al.: Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol 2001; 8: pp. 384-391.</p><li><p>12. Lemort M., Canizares-Perez A.C., Van der Stappen A., Kampouridis S.: Progress in magnetic resonance imaging of brain tumours. Curr Opin Oncol 2007; 19: pp. 616-622.</p><li><p>13. Nelson S.J., Cha S.: Imaging glioblastoma multiforme. Cancer J 2003; 9: pp. 134-145.</p><li><p>14. Puduvalli V.K., Sawaya R.: Antiangiogenesis—therapeutic strategies and clinical implications for brain tumors. J Neurooncol 2000; 50: pp. 189-200.</p><li><p>15. Folkman J.: The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: pp. 65-71.</p><li><p>16. Okunieff P., Dols S., Lee J., et. al.: Angiogenesis determines blood flow, metabolism, growth rate, and ATPase kinetics of tumors growing in an irradiated bed: 31P and 2H nuclear magnetic resonance studies. Cancer Res 1991; 51: pp. 3289-3295.</p><li><p>17. Estrada G., González-Maya L., Celis-López M.A., et. al.: Diagnostic approach in suspected recurrent primary brain tumors using (18)FDG-PET/MRI, perfusion MRI, visual and quantitative analysis, and three dimensional stereotactic surface projections. First experience in Mexico. Rev Esp Med Nucl 2008; 27: pp. 329-339.</p><li><p>18. Sugahara T., Korogi Y., Tomiguchi S., et. al.: Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000; 21: pp. 901-909.</p><li><p>19. Fuss M., Wenz F., Scholdei R., et. al.: Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence. Int J Radiat Oncol Biol Phys 2000; 48: pp. 53-58.</p><li><p>20. Lev M.H., Ozsunar Y., Henson J.W., et. al.: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas. AJNR Am J Neuroradiol 2004; 25: pp. 214-221.</p><li><p>21. Fitzek M.M., Thornton A.F., Rabinov J.D., et. al.: Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999; 91: pp. 251-260.</p><li><p>22. Fitzek M.M., Thornton A.F., Harsh G.T., et. al.: Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial. Int J Radiat Oncol Biol Phys 2001; 51: pp. 131-137.</p><li><p>23. Pardo F.S., Aronen H.J., Fitzek M., et. al.: Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res 2004; 24: pp. 2359-2365.</p><li><p>24. Aronen H.J., Pardo F.S., Kennedy D.N., et. al.: High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6: pp. 2189-2200.</p><li><p>25. Kwong K.K., Chesler D.A., Weisskoff R.M., et. al.: MR perfusion studies with T1-weighted echo planar imaging. Magn Reson Med 1995; 34: pp. 878-887.</p><li><p>26. Petersen E.T., Zimine I., Ho Y.C., Golay X.: Non-invasive measurement of perfusion: a critical review of arterial spin labelling techniques. Br J Radiol 2006; 79: pp. 688-701.</p><li><p>27. Aronen H.J., Gazit I.E., Louis D.N., et. al.: Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191: pp. 41-51.</p><li><p>28. Weisskoff R., Rosen B.R.: Functional magnetic resonance imaging. Acad Radiol 1995; pp. 133-135.</p><li><p>29. Lev M.H., Rosen B.R.: Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin North Am 1999; 9: pp. 309-331.</p><li><p>30. Provenzale J.M., Wang G.R., Brenner T., Petrella J.R., Sorensen A.G.: Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002; 178: pp. 711-716.</p><li><p>31. Covarrubias D.J., Rosen B.R., Lev M.H.: Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004; 9: pp. 528-537.</p><li><p>32. Song C.W., Lokshina A., Rhee J.G.: Implication of blood flow in hyperthermic treatment of tumors. IEEE Trans Biomed Eng 1984; 31: pp. 9-16.</p><li><p>33. Sadeghi N., Salmon I., Tang B.N., et. al.: Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imagin 2006; 24: pp. 989-994.</p><li><p>34. Spampinato M.V., Smith J.K., Kwock L., et. al.: Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007; 188: pp. 204-212.</p><li><p>35. Knopp E.A., Cha S., Johnson G., et. al.: Glial neoplasms: dynamic contrast-enhanced T2∗-weighted MR imaging. Radiology 1999; 211: pp. 791-798.</p><li><p>36. Uematsu H., Maeda M., Sadato N., et. al.: Blood volume of gliomas determined by double-echo dynamic perfusion-weighted MR imaging: a preliminary study. AJNR Am J Neuroradiol 2001; 22: pp. 1915-1919.</p><li><p>37. Aronen H.J., Perkio J.: Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin North Am 2002; 12: pp. 501-523.</p><li><p>38. Warmuth C., Gunther M., Zimmer C.: Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003; 228: pp. 523-532.</p><li><p>39. Dean B.L., Drayer B.P., Bird C.R., et. al.: Gliomas: classification with MR imaging. Radiology 1990; 174: pp. 411-415.</p><li><p>40. Bagley L.J., Grossman R.I., Judy K.D., et. al.: Gliomas: correlation of magnetic susceptibility artifact with histologic grade. Radiology 1997; 202: pp. 511-516.</p><li><p>41. Miralbell R., Lomax A., Russo M.: Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation. Int J Radiat Oncol Biol Phys 1997; 38: pp. 805-811.</p><li><p>42. Forsyth P.A., Kelly P.J., Cascino T.L., et. al.: Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful?. J Neurosurg 1995; 82: pp. 436-444.</p><li><p>43. Pauliah M., Saxena V., Haris M., Husain N., Rathore R.K., Gupta R.K.: Improved T(1)-weighted dynamic contrast-enhanced MRI to probe microvascularity and heterogeneity of human glioma. Magn Reson Imaging 2007; 25: pp. 1292-1299.</p><li><p>44. Sugahara T., Korogi Y., Kochi M., et. al.: Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171: pp. 1479-1486.</p><li><p>45. Aronen H.J., Glass J., Pardo F.S., et. al.: Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility. Acta Radiol 1995; 36: pp. 520-528.</p><li><p>46. Wolf R.L., Wang J., Wang S., et. al.: Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 2005; 22: pp. 475-482.</p><li><p>47. Gasparetto E.L., Pawlak M.A., Patel S.H., et. al.: Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 2009; 250: pp. 887-896.</p><li><p>48. Calamante F., Thomas D.L., Pell G.S., et. al.: Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab 1999; 19: pp. 701-735.</p><li><p>49. Cavuşoğlu M., Pfeuffer J., Uğurbil K., Uludağ K.: Comparison of pulsed arterial spin labeling encoding schemes and absolute perfusion quantification. Magn Reson Imaging 2009; 27: pp. 1039-1045.</p><li><p>50. Gevers S., Majoie C.B., van den Tweel X.W., Lavini C., Nederveen A.J.: Acquisition time and reproducibility of continuous arterial spin-labeling perfusion imaging at 3 T. AJNR Am J Neuroradiol 2009; 30: pp. 968-971.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-17/'>Volume 17</a>, <a href='/categories/issue-3/'>Issue 3</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Glioma%20Recurrence%20Versus%20Radiation%20Necrosis?%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fglioma-recurrence-versus-radiation-necrosis%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Glioma%20Recurrence%20Versus%20Radiation%20Necrosis?%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fglioma-recurrence-versus-radiation-necrosis%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fglioma-recurrence-versus-radiation-necrosis%2F&text=Glioma%20Recurrence%20Versus%20Radiation%20Necrosis?%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/brain-imaging/"><div class="card-body"> <em class="small" data-ts="1267376400" data-df="ll" > Feb 28, 2010 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Brain Imaging</h3><div class="text-muted small"><p> Brain Imaging is an installment of the Dx-Direct: Direct Diagnosis in Radiology series published by Thieme. This book limits its scope to imaging of the brain. Spine and head/neck imaging are cover...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-conventional-abdominal-ct-with-mr-enterography-in-patients-with-active-crohn-s-disease/"><div class="card-body"> <em class="small" data-ts="1267376400" data-df="ll" > Feb 28, 2010 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of Conventional Abdominal CT with MR-Enterography in Patients with Active Crohn's Disease and Acute Abdominal Pain</h3><div class="text-muted small"><p> Rationale and Objectives Patients with known Crohn’s disease (CD) and an acute onset of severe abdominal pain attending an emergency room frequently undergo contrast-enhanced emergency computed to...</p></div></div></a></div><div class="card"> <a href="/posts/computer-aided-diagnosis-of-lung-nodules-on-ct-scans/"><div class="card-body"> <em class="small" data-ts="1267376400" data-df="ll" > Feb 28, 2010 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Computer-Aided Diagnosis of Lung Nodules on CT Scans</h3><div class="text-muted small"><p> Rationale and Objectives The aim of this study was to evaluate the effect of computer-aided diagnosis (CAD) on radiologists’ estimates of the likelihood of malignancy of lung nodules on computed t...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/flexner-report-on-medical-education/" class="btn btn-outline-primary" prompt="Older"><p>Flexner Report on Medical Education</p></a> <a href="/posts/incremental-value-of-111-in-pentetreotide-spect-ct-fusion-imaging-of-neuroendocrine-tumors/" class="btn btn-outline-primary" prompt="Newer"><p>Incremental Value of 111-In Pentetreotide SPECT/CT Fusion Imaging of Neuroendocrine Tumors</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
